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Abstract
Plants have been shown to be an excellent source of new drugs, including
anticancer agents. Rhus coriaria, commonly known as sumac, a plant that is known to
possess different therapeutic values including anti-oxidant and anti-microbial
activities. Here, we investigated the anti-cancer effect of R. coriaria on triple negative
MDA-MB-231 cell line. We demonstrated that Rhus coriaria ethanolic extract (RCE)
inhibits the proliferation of MDA-MB-231 cell line in a time- and concentrationdependent manner. RCE induced senescence and cell cycle arrest at G1 phase.
Moreover, no proliferative recovery was detected after RCE removal. Annexin V
staining and PARP cleavage analysis revealed a minimal induction of apoptosis in
MDA-MB-231 cells. Autophagy vacuoles were detected along with autophagy
markers. Interestingly, blocking autophagy by 3-methyladenine (3-MA) or
chloroquine (CQ) reduced RCE-induced cell death and senescence. Finally, RCE
induced DNA damage, an event that was found to precede autophagy. Hence,
altogether, these findings make Rhus coriaria a promising alternative candidate
against breast cancer.

Keywords: Rhus coriaria, triple negative breast cancer, apoptosis, senescence, cell
cycle, autophagy, DNA damage.
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)Title and Abstract (in Arabic

أثر نبات السماق المضاد لسرطان الثدي
الملخص

تستخدم النباتات في صنع األدوية الجديدة التي تتضمن مضادات السرطان .أحد هذه
النباتات هو نبات ال ) (Rhus coriariaو يعرف بنبات السماق .أشارت الدراسات السابقة على
فاعلية نبات السماق كعالج مضاد لألكسدة ومضاد حيوي .وبالتالي قمنا في هذه األطروحة بدراسة
أثر مستخلص السماق على سرطان الثدي .ولقد توصلنا في هذا الدراسة إلى أن نبات السماق يمنع
نمو وتكاثر الخاليا السرطانية ) (MDA-MB-231باالعتماد على الوقت والتركيز .كما أنه أدى
إلى إيقاف دورة حياة الخلية ) (cell cycle arrestوإلى الشيخوخة ) (senescenceفي الخاليا
السرطانية .باإلضافة إلى ذلك فإن نبات السماق منع تكاثر الخاليا السرطانية بعد إزالة السماق بل
وأدى إلى موتها حتى بعد إزالة السماق من الخاليا .لقد وجدنا أن بعض الخاليا تموت بعملية
الموت الذاتي ) ،(apoptosisولكن العملية الرئيسية التي وجدناها لموت الخاليا السرطانية هي
الموت الذاتي للخاليا ) .(autophagyوعندما منعنا عملية الموت الذاتي بمواد كيميائية خاصة3-
) MAأو  (CQقلت نسبة الشيخوخة وموت الخاليا .كما وجدنا أن السماق يؤدي إلى إلحاق
الضرر بالحمض النووي ) (DNA damageالخاص بالخاليا السرطانية .كل هذه النتائج تجعل
نبات السماق بديل واعد كمضاد لسرطان الثدي.
مفاهيم البحث الرئيسية :نبات السماق ،الشيخوخة ،دورة حياة الخلية،الموت المبرمج للخاليا،
الموت الذاتي للخاليا ،ضرر الحمض النووي.
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Chapter 1: Introduction
1.1 Cancer
Cancer remains one of the leading causes of morbidity and mortality. It is a
major public health problem worldwide. An estimated 14.1 million new cancer cases
were diagnosed worldwide in 2012. Sadly, 8.2 million deaths from cancer occurred in
the same year. Moreover, it is predicted that by 2020 cancer rates could further increase
by 50% to reach 15 million new cases[1]. In the United Arab Emirates, 1212 new
cancer cases were reported in 2012. Cancer is the second leading cause of death in the
Emirate of Abu Dhabi, and accounts for 15% of total deaths as there were around 407
deaths caused by cancer in 2012[2].
1.1.1 Definition and classification
Cancer is defined as a multifactorial disease that is characterized by
uncontrolled cellular growth, invasion and spreading of those cells from their primary
site to other sites in the body to establish new colonies of cancer cells[3]. Cancers are
classified upon their tissue of origin. The most common of them are carcinomas which
arise from epithelial cells, while sarcomas are derived from mesoderm cells. Cancers
of epithelial cells with glandular organization are called adenocarcinomas[3]. Other
classes of cancers include lymphoma and leukaemia are derived from white blood cells
and their precursors[4].
1.1.2 Hallmarks of cancer
Cancer cells are distinguished from normal cells by acquiring specific
hallmarks. These hallmarks include stimulating their own growth by responding to

2

their own signals, sustaining proliferative signalling and resisting inhibitory signals
that might otherwise stop their growth. In addition, evading apoptosis and enabling
unlimited replicative potential, stimulating angiogenesis, by forming blood vessels to
supply nutrients to tumors, invading local tissues and metastasize to distant sites.
Furthermore, reprogramming of energy metabolism and evading immune system
destruction are emerging hallmarks of cancers that need further study[5].
1.1.3 Causes of cancer
While the real cause of cancer is still unknown, many factors have been
associated with cancer. These factors include genetic mutation in tumor suppressor
genes and oncogenes, life style, chemical agents and viruses[3].
1.2 Breast cancer
Breast cancer represent the most commonly diagnosed cancers in women.
There were 1.7 million new cases diagnosed in 2012 worldwide. This represents about
12% of all cancer cases and 25% of all cancers in women[6]. In the United Arab
Emirates the leading cause of death related to cancer for the same year was breast
cancer as well[2]. Breast cancers are a heterogeneous and diverse group of diseases
that comes in several clinical and histological implications. The clinical progression
of breast cancer is difficult to predict and its current treatment is therefore not as
effective as it should be[7], [8]. Gene expression profiling using microarray analysis
assists in creating a working model for a breast cancer molecular taxonomy which has
become widely used. Using hierarchical cluster analysis breast cancers can be
classified into one of five molecular subtypes: luminal A and luminal B –both are
estrogen receptor (ER)-positive- , basal-like (ER)-negative, human epidermal growth
factor receptor 2 (HER2) overexpression , and normal breast-like[7],[9]–[11].
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1.2.1 Triple negative breast cancer
Triple-negative breast cancers (TNBCs) represent a heterogeneous subtype of
breast cancers that are associated with an aggressive clinical conditions and poor
prognosis, where targeted therapies are currently limited[12]. The majority of TNBCs
belong to the basal-like category. Their clinical and pathologic features overlap with
hereditary BRCA1 related breast cancers[13], [14]. TNBCs are characterized by the
absence of ER, progesterone receptor (PR) and lack of HER2 expression[15].
Therefore, TNBCs have more aggressive clinical course than other forms of breast
cancers, with an increased likelihood of recurrence and death[16].
1.3 Molecular mechanisms targeted in cancer
Several cellular processes and molecular mechanisms are targeted in cancer
treatment. These mechanisms include DNA damage, cell cycle, senescence and cell
death.
1.3.1 DNA damage
DNA damage is an alteration in DNA which can be caused by different
stressors. These stressors include radiations such as UV light and X-rays, chemicals
and reactive oxygen species (ROS)[17]. In response to such stresses, cells activate
several mechanisms to repair DNA and maintain genomic integrity[18], [19]. If DNA
damage was beyond the cell’s repair capacity, then cell cycle arrest and/or cell death
might occur to eliminate potentially dangerous mutations[20]. One example of DNA
damage is double strand breakages that are detected by γH2AX marker. H2AX histone
variant becomes rapidly phosphorylated, upon double strand breaks, at serine 139 to
form γH2AX that act as a signal for the recruitments of proteins involved in DNA
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repair and chromatin remodelling[21],[22]. As the double strand breakages are
repaired, dephosphorylation of γH2AX occur and the cell goes into its normal
state[23], [24].
1.3.1.1 DNA damage and cancer
Accumulation of DNA damage that is beyond repair capacity, or defect in DNA
repair pathways leads to mutations or chromosomal aberrations that affect oncogenes
and tumor suppressor genes. As a result, cells could undergo malignant transformation
into cancer[25]. In cancer cells, defects in DNA repair pathways enable cancer cells to
accumulate genomic alterations that contribute to their aggressive phenotype[26].
Alterations in DNA repair pathways can make some cancer cells depend on less DNA
repair pathways for survival. Moreover, there are specific DNA repair pathways that
enable cancer cells to survive DNA damage that is induced by chemotherapeutic
treatments, making them resistant to such drugs[27].
1.3.2 Cell cycle
Cancer is characterized by uncontrolled proliferation and dysregulated cell
cycle control. Cell proliferation involves the reproduction of a cell to form two
daughter cells[28]. Cell cycle consists of distinct phases. The major phases are S and
M phases. In S phase, DNA is replicated and chromosomes are duplicated. While M
phase consists of two events: nuclear division (mitosis) and cell division (cytokinesis).
Interphase comprises the end of M phase and the beginning of the next. Most cell
cycles includes gap phases in between S and M phases. G1 occurs before S phase and
G2 before M phase. Gap phases provide additional time for cells to grow. It also serve
as regulatory transitions that controls the progression to the next stage of cell cycle.
G1 is an important phase in which cell is committed into continued division or exit
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from cell cycle. In the presence of unfavorable growth conditions cells go into
prolonged G1 or exit into non-dividing state called G0[29].
1.3.2.1 Control system
Cell cycle is controlled by a regulatory network[30]. The changes in gene
expression as a function of cell cycle progression are regulated by specific cyclin
dependent kinases (CDKs) activities[31]. CDKs are protein kinase subunits that forms
complexes with a regulatory cyclin proteins. Cyclins are synthesized and destroyed at
specific times during cell cycle, thus regulating kinase activity. Human cells contain
multiple CDKs and cyclins. However, only certain subset of CDK–cyclin complexes
are directly involved in driving the cell cycle. They include three interphase CDKs
(CDK2, CDK4 and CDK6), a mitotic CDK (CDK1, also known as cell division control
protein 2 (CDC2)) and ten cyclins that belong to four different classes (the A, B, D
and E cyclins)[32], [33].
1.3.2.1.1 Checkpoints
There are two crucial aspects of cell cycle regulation: DNA structure
checkpoints, which arrest the cell cycle in response to DNA damage or incomplete
replication, and commitment point in which a cell becomes committed to enter the cell
cycle and progress through it independently of signals from the environment[34].
DNA checkpoints sense possible defects during DNA synthesis and chromosome
segregation. They respond to internal stresses such as incomplete replication or
external stresses such as DNA damaging agents to block cell cycle progression. Cell
cycle arrest allows cells to properly repair these defects, thus preventing their
transmission to the resulting daughter cells[35].
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The major checkpoints are DNA damage checkpoints: at entry into S phase
(G1–S checkpoint) and mitosis (G2–M checkpoint), and the spindle checkpoint that
controls progression into anaphase[28]. DNA damage checkpoints protect cells from
exogenous and endogenous genotoxic agents that induce diverse alterations in the
DNA molecule. These alterations are sensed by signalling pathways that ultimately
leads to CDK inhibition and cell cycle arrest[36]. If repair is unsuccessful because of
the excessive DNA damage or genetic defects in either the checkpoint or the DNA
repair machinery, cells may enter senescence or undergo apoptosis[37]. Spindle
assembly checkpoint controls the proper segregation of the chromosomes once the
genetic material is duplicated. It has a signalling pathway that modulates CDK1
activity and prevent defects in chromosome segregation[38], [39].
1.3.2.2 Cell cycle and cancer
The loss of checkpoint controls in cancer cells make them less sensitive to the
normal growth signals that regulate normal cell proliferation. Tumor cells accumulate
mutations that result in constitutive growth signalling and defective responses to antigrowth signals that contribute to unscheduled proliferation[32], [33], [40]. Most
tumors acquire genomic instability that leads to additional mutations as well as
chromosomal instability[37], [38]. These alterations result in proliferative advantages
and increased susceptibility to the accumulation of additional genetic alterations that
contribute to tumor progression and acquisition of more aggressive phenotypes. Cell
cycle defects are mediated, directly or indirectly, by misregulation of CDKs[41].
1.3.3 Senescence
Senescence was first described by Hayflick and Moorhead as they showed that
cells have limited ability to proliferate[42]. Mitotically competent cells respond to
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various stressors by undergoing cellular senescence as shown in Figure 1[43]. Cells
loose the ability to proliferate while remaining alive.[44]. Senescent cells adopt
morphological changes that are characterized by flattened shape and enlarged size[43],
[45]. Senescent cells exhibit specific molecular markers such as senescence-associated
β-galactosidase

(SA-β-gal)

and

senescence-associated

heterochromatin

foci

(SAHF)[46], [47]. SA-β-gal activity is known to be increased in senescent cells. This
increase is likely due to an increased lysosomal content of senescent cells, giving rise
to an elevated β-galactosidase activity that becomes detectable at pH 6[45], [48].
However, there is no evidence on the actual involvement of this enzyme in senescence
pathway[49].

Figure 1: The senescent phenotype induced by multiple stimuli[43].
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1.3.3.1 Senescence and cancer
Mouse models of cancer have demonstrated that senescence is associated with
pre-malignant stages of neoplastic transformation and has a crucial function in
preventing tumor progression. Interestingly, senescent tumor cells are not only growth
arrested but can be also cleared by phagocytic cells[50]. Loss or inactivation of tumor
suppressor genes are associated with impaired senescence[51]. Therapeutic
approaches such as p53-tumor suppressor gene- reactivation, inhibition of c-MYConcogene- in tumors or treatment with cyclin-dependent kinase (CDK) inhibitors have
proven to be effective by stimulating a senescence response[52]. Therefore, malignant
tumors, despite their impaired ability to undergo senescence, can still be forced into
senescence if crucial oncogenic pathways are disabled or tumor suppressors are
restored. Therefore, senescence-inducing drugs could represent an ideal opportunity
to increase the arsenal of anticancer weapons[51].
1.3.4 Programed cell death
Programmed cell death (PCD) is essential for the development and
maintenance of multicellular organisms. Two self-destructive processes, autophagy
(‘self-eating’) and apoptosis (‘self-killing’), have captivated the imagination of
scientists. Thus, apoptosis and autophagy constitute two processes through which
damaged or aged cells or organelles are eliminated[53].
1.3.4.1 Apoptosis (programmed cell death I)
Apoptosis is a tightly regulated multi-step pathway responsible for cell death
not only during development, but also in adult multicellular organisms to maintain
homeostasis. Key characteristics of apoptosis are cellular shrinkage, condensation of
the nucleus and DNA fragmentation[54], [55] . Cells that undergo apoptosis initially
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become rounded and retracted from neighboring cells which is accompanied by plasma
membrane blebbing[56], [57]. A dominant signal of apoptosis is the translocation of
phosphatidylserine from the inner to the outer side of the plasma membrane. This ‘eatme’ indicator functions as a recognition signal for phagocytic cells to engulf apoptotic
cells[58]. Apoptosis occur in a controlled manner to minimize damage and disruption
to neighboring cells[54]. Apoptosis is orchestrated primarily, but not exclusively, by
members of cysteine proteases family known as caspases[59].
1.3.4.1.2 Apoptosis and cancer
To cope with DNA damage, cells have evolved a sophisticated repair system.
Failure of this system leads to genomic instability, which triggers apoptosis under
normal physiological circumstances. Mutations in key apoptosis signalling proteins
and oncogene activation result in evading apoptosis, which ultimately lead to tumor
development[58].
1.3.4.2 Autophagy (programmed cell death II)
Autophagy is a highly regulated process that can either be involved in the
turnover of long-lived proteins and whole organelles or can specifically target distinct
organelles (for example, mitochondria in mitophagy and the endoplasmic reticulum
(ER)

in

reticulophagy),

thereby

eliminating

supernumerary

or

damaged

organelles[60].
Autophagy can act as cellular survival mechanism or cell death. Autophagy can
protect cells against death, as a cytoprotection mechanisms, autophagy mediates the
removal of protein aggregates that otherwise will lead to cellular dysfunction. On the
other hand, autophagy can mediate cellular death. One way by killing, where
autophagy destroys large proportions of the cytosol and organelles that would cause
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irreversible cellular atrophy with a consequent collapse of vital cellular functions.
Indeed, during extensive autophagy, the volume that is occupied by autophagic
vacuoles and dense bodies may be roughly equal to, or greater than, that of ‘free’
cytosol and organelles. Autophagy can also mediate cellular death by triggering
apoptosis or necrosis as a primary response to stress stimuli[61], [62].
1.3.4.2.1 Mechanism of autophagy
Autophagy starts with the engulfment of cytoplasmic material by the
phagophore inside an intact cell, which sequesters material in double-membraned
vesicles named autophagosomes.
Among the initial steps of vesicle nucleation is the activation of Vps34, a class
III phosphatidylinositol 3‑kinase (PI3K), to generate phosphatidylinositol-3phosphate (PtdIns3P). Vps34 activation depends on the formation of a multiprotein
complex in which beclin-1 is involved. This complex recruits autophagy related genes
(Atg) that are essential for autophagosome formation. Atg 5, 7 and 8 complex
promotes the recruitment and conversion of the cytosolic microtubule-associated
protein light chain 3-I (LC3-I) into LC3-II by cysteine protease Atg4. LC3-II will be
incorporated into the autophagosome membrane[53], [63]. A simplified scheme of
autophagy mechanism is illustrated in Figure 2[64]. LC3-II also binds to the adaptor
protein p62/sequestosome1 (SQSTM 1), which is involved in trafficking proteins to
the proteasome and serves to facilitate the autophagic degradation of ubiquitinated
protein aggregates[65]. p62/SQSTM 1 is normally degraded during autophagy and
accumulates when autophagy is impaired, as has been shown in autophagy-deficient
mice[66]. Autophagosomes undergo maturation by fusion with lysosomes to form
autolysosomes. In the autolysosomes, the inner membrane as well as the luminal
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content of the autophagic vacuoles is degraded by lysosomal enzymes that act
optimally within this acidic compartment[67].

Figure 2: Simplified mechanism of autophagy[64].

1.3.4.2.2 Autophagy and cancer
The role of autophagy in cancer is multifactorial and highly context-dependent.
Autophagy is recognized as a survival factor for tumor cells under certain metabolic
and therapeutic stresses[63]. However, genetic evidence suggested that autophagy
plays a role in tumor suppression[68]. It was proposed that autophagy functions as a
tumor suppressor at early stages of tumor development, since the expression of beclin1, was found to reduce tumorigenesis through induction of autophagy. Conversely,
autophagy was found to promote tumor progression at later stages of tumor to survive
low-oxygen and low-nutrient conditions. Moreover, it was established that autophagy
protects some cancer cells against anti-cancer drugs by blocking the apoptotic
pathway. In contrast, other cancer cells undergo autophagic cell death after cancer
therapies[69].
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1.4 Conventional therapy
Different types of cancer therapy are used for cancer treatment depending on
cancer type and stage. These treatments include the following: surgery, radiotherapy,
chemotherapy.,etc. Surgery aims to remove localized primary tumors. In radiotherapy,
ionizing radiation are used to target tumor cells where they react with water to generate
reactive oxygen spices (ROS) that damage the DNA[3]. Chemotherapy aims to target
highly proliferative cancerous cells.
1.5 Alternative therapy
Therapies used nowadays to treat breast cancer has definitely improved
patients’ disease status. However, the side effects that are accompanied with such
treatments, sometimes lead to death, beside, aggressive metastasized cancer remains
untreatable. Therefore, novel therapeutic options are needed to target aggressive type
of breast cancer with less side effects.
1.5.1 Plants
Plants have been used as medicine for many diseases throughout the years.
They were shown to be a source of new drugs, including anticancer drugs. There are
compelling evidences from epidemiological and experimental studies that highlight
the importance of compounds derived from plants “phytochemicals” to reduce the risk
of several cancers and inhibit the development of tumors in experimental animals.
With advanced knowledge of molecular science and improvement in isolation and
purification techniques, many anticancer agents derived from medicinal plants have
been identified and developed. More than 25% of drugs used during the last 20 years
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are directly derived from plants, while another 25% are chemically altered natural
products[70].
Anticancer drugs derived from plants includes taxol isolated from the bark of
Taxus brevifolia Nutt, vinblastine and vincristine isolated from Catharanthus roseus,
camptothecin derivatives isolated from the Chinese Camptotheca acuminata Decne,
and etoposide derived from epipodophyllotoxin are in clinical use. Several other types
of promising bioactive compounds of plant origin are currently in clinical trials or
preclinical trials or undergoing further investigation[71].
Moreover, recent studies have tested the crude extract of herbal plants to test
their anti-cancer effects. For example Origanum majorana extract was found to inhibit
the viability of triple negative MDA-MB-231 breast cancer cells confirmed by colony
growth inhibition, and induced cell cycle arrest in M phase at lower concentration. At
higher concentration, apoptosis was induced through the extrinsic apoptotic pathway.
Moreover, Origanum majorana extract was found to induce DNA damage[72].
In addition to that, several other studies revealed the use of herbal crude
extracts to have anti-breast cancer activities. For instance, the aqueous extract of
Fagonia cretica, used widely as herbal tea, induced cell cycle arrest and apoptosis in
MCF-7 and MDA-MB-231 breast cancer cell lines, with activation of DNA damage
response[73]. Huanglian extract (Coptidis rhizoma), a widely used herb in Chinese
medicine, inhibited cellular growth and apoptosis by upregulation of interferon-β and
TNF-α in MCF-7 breast cancer cells [74]. Dillenia suffruticosa (Griff) ethyl acetate
extract caused cytotoxicity to MCF-7 cells and induced apoptosis by modulating
several genes which are involved in oxidative stress pathway[75]. An ideal
phytochemical is one that possesses anti-tumor properties with minimal or no toxicity
and has a defined mechanism of action[76].
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1.5.1.1 Rhus coriaria Linn
Rhus coriaria Linn, commonly known as sumac, belongs to Anacardiacea
family. R. coriaria is widely distributed in temperate and subtropical regions[77]. It is
considered to be a flowering shrub where the fruit forms clusters of reddish drupes[78].
R. coriaria is known to have therapeutic values and dietary qualities; it is used as a
medicinal herb, spice and sour drink[79].
1.5.1.1.1 Rhus coriaria phytochemicals
According to Abu-Reidah et.al, (2014), 211 phytochemical compounds have
been characterized using HPLC–DAD–ESI-MS/MS method. These phytochemicals
are organic acids, phenolic acids, phenolic compounds conjugated with malic acid
derivatives, flavonoid, isoflavonoid, hydrolysable tannins, anthocyanins, terpenoid
and other compounds (such as butein, iridoid and coumarin derivatives) [80].
1.5.1.1.2 Rhus coriaria mechanism of action
R. coriaria is considered to be a natural antioxidant; it has the capacity to
protect cells and organisms against damage caused by oxidative stress. Previous
studies indicated that antioxidant activities of R. coriaria extract was due to the
presence of phenolic compounds[77], [81]. Several studies linked the accumulation of
ROS in the body to different diseases such as atherosclerosis[82], insulin resistance,
type II diabetes[83], cardiovascular diseases[84], osteoarthritis[85], hepatocytes
toxicity[86] and DNA damage[87]. Interestingly, R. coriaria extract was found to have
an effect in all the above mentioned diseases. Moreover, it was shown that R. coriaria
extract induced hypoglycemic activity in type II diabetic rats; as it reduced the
postprandial blood glucose (PBG)[88]. In addition, it has antimicrobial activity
against gram positive and gram negative bacteria, by causing irreversible damage to
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bacteria[89]. A recent study illustrated the cytotoxic and antiangiogenic effects of R.
coriaria methanolic extract on Y79 retinoblastoma cell line[90].
The aim of this study is to investigate the anti-breast cancer effect of R.
coriaria on triple negative, highly invasive MDA-MB-231 cell line.
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Chapter 2: Materials and Methods
2.1 Cell culture, chemicals and antibodies
Human breast cancer cells MDA-MB-231 and MCF-7 were maintained in
DMEM (Hyclone, Cramlington, UK) and T47D in RPMI (Hyclone, Cramlington,
UK). All media were complemented with 10% fetal bovine serum (FBS) (Hyclone,
Cramlington, UK) and 100 U/ml penicillin/streptomycin (Hyclone, Cramlington,
UK). 3-methyadenine (3-MA) and chloroquine (CQ) were purchased from Millipore
Analyzer (Millipore, Hayward, CA, USA) and Sigma-Aldrich (Saint-Quentin
FAllavier, France), respectively. Antibodies to p62/SQSTMI and cleaved PARP
were obtained from Abcam (Abcam, Cambridge, UK). Antibodies to LC3 was
obtained from Cell Signaling (USA). Antibodies to γH2AX and Beclin-1 were
obtained from Millipore (Millipore, Hayward, CA, USA). Antibody to β-actin were
obtained from Santa Cruz Biotechnology, Inc (USA).

2.2 Preparation of the Rhus coriaria ethanolic extract (RCE)
Fruits of Rhus coriaria L. were collected from a private farm located at 33°
16′ 35.59′′ N and 35° 19′ 02.89′′ E. The farm is located in Ma’rakeh, Tyre, Lebanon
and the approval of the owner was obtained before collecting the fruit or
commencing any experiments. This plant is neither endangered nor protected by any
laws and it is readily and commercially available in the market. RCE was prepared
as previously described[72]. Briefly 10.0 g of the dried fruit were ground to a fine
powder using a porcelain mortar and pestle. The powder was then suspended in
100 mL of 70% absolute ethanol and the mixture was kept in the dark for 72 hours
at 4 °C in a refrigerator without stirring. After that, the mixture was filtered through
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a glass sintered funnel and the filtrate was evaporated to dryness using a rota-vapor
at room temperature. The red residue was kept under vacuum for 2–3 hours and its
mass was recorded. The residue was stored at −20 °C until further use.

2.3 Measurement of cellular viability
Cells were seeded in triplicate in 96-well plates at a density of 5,000
cells/well. After 24 h of culture, cells were treated with or without various
concentrations of Rhus coriaria extract for different durations. Cell viability was
measured with the Cell Cytotoxicity Assay Kit (Abcam) according to the
manufacturer’s specifications. The results are representative of an average of 5
independent experiments. Data were presented as proportional viability (%) by
comparing the treated group with the untreated cells, the viability of which is
assumed to be 100%.

Cell viability was also measured using the Muse™ Cell Analyzer (Millipore,
Hayward, CA, USA) using the Muse Count and Viability Kit (Millipore, Hayward,
CA, USA) which differentially stains viable and dead cells based on their
permeability to two DNA binding dyes. Briefly, cells were plated onto 12-well
plates (50 × 104 cells/well) and allowed to grow for 24 h. The day of treatment cells
were counted to estimate the approximate number of cells per well. Following RCE
treatment at indicated times, viable cells were counted using Muse™ Cell Analyzer.

2.4 Cell cycle analysis
The cell cycle distribution analysis in control and RCE-treated MDA-MB231 cells was performed with the Muse™ Cell Analyzer (Millipore, Hayward, CA,
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USA) using the Muse™ Cell Cycle Kit (Millipore, Hayward, CA, USA) according
to the manufacturer’s instructions. Briefly, cells grown onto 6 cm culture dishes
were treated with or without various concentrations of RCE. After 24 h or 48 h of
treatment, cells were collected by trypsinization, washed in PBS and resuspended
in complete media and the Muse cell cycle test reagent was then added to each test
tube. Cells were then incubated for 30 min at room temperature in the dark. After
staining, the cells were processed for cell cycle analysis. Percentage of cells in
G0/G1, S and G2/M phases were determined using the FlowJo software.

2.5 Quantification of apoptosis by Annexin V labelling
Apoptosis was examined using the Annexin V & Dead Cell kit (Millipore,
Hayward, CA, USA) according to the manufacturer’s instructions. Briefly, MDAMB-231 cells were treated with or without RCE for 48 h. Detached and adherent
cells were collected and incubated with Annexin V and 7-AAD, a dead cell marker,
for 20 min at room temperature in the dark. The events for live, early and late
apoptotic cells were counted with the Muse™ Cell Analyzer (Millipore, Hayward,
CA, USA).

2.6 Hematoxylin-eosin staining of cells
MDA-MB 231 cells (5 × 104) were grown on 2 well labtek chamber slide for
24 h, then treated with and without RCE for 48 h. Cells were then washed twice with
PBS and fixed in 10% formalin solution (4% paraformaldehyde) for 5 min at room
temperature followed by permeabilization in 70% ethanol. Cells were then washed
three times with PBS, stained with hematoxylin for 1 min and washed again before
staining with eosin for 30 seconds. For viewing the cells, slides were mounted with
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50% glycerol, sealed and observed under Olympus microscope (BX41) fitted with
Olympus camera (DP71).

2.7 Senescence-Associated-β-Galactosidase (SA-β-gal) staining
Briefly 105 MDA-MB-231 cells were cultured in 6 well plate and treated
with and without RCE for 48 h. Treated and control cells were then washed in PBS,
and fixed with 2% formaldehyde/0.2% glutaraldehyde for 5 min at room
temperature. The SA-β-gal staining was performed as previously described.

2.8 Whole cell extract and western blotting analysis
Cells (1.8 × 106) were seeded in 10 cm culture dishes and cultured for 24 h
before addition of RCE. After incubation, cells were washed twice with ice-cold
PBS, scraped, pelleted and lysed in RIPA buffer (Pierce) supplemented with
protease inhibitor cocktail (Roche) and phosphatase inhibitor (Roche). After
incubation for 30 min on ice, cell lysates were centrifuged at 14,000 rpm for 20 min
at 4 °C. Protein concentration of lysates was determined by BCA protein assay kit
(Thermo Scientific) and the lysates were adjusted with lysis buffer. Aliquots of
25 μg of total cell lysate were resolved onto 8–15% SDS-PAGE. Proteins were
transferred to nitrocellulose membranes (Thermo Scientific) and blocked for 1 h at
room temperature with 5% non-fat dry milk in TBST (Tris-buffered saline with
0.05% Tween 20). Incubation with specific primary antibodies was performed in
blocking buffer overnight at 4 °C. Horseradish peroxidase-conjugated anti-IgG was
used as secondary antibody. Immunoreactive bands were detected by ECL
chemiluminescent substrate (Thermo Scientific). Where needed, membranes were
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stripped in Restore western blot stripping buffer (Thermo Scientific) according to
the manufacturer’s instructions.

2.9 Statistical analysis
The statistical analysis were done using SPSS version 21. Data were reported
as group mean ± SEM. The data were analyzed via t-test, univariate test and oneway ANOVA followed by LSD’s Post-Hoc multiple comparison test (to compare
all groups). Significance for all statistical comparisons was set at p < 0.05 using a
two-tailed test.
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Chapter 3: Results
3.1 The inhibitory effect of Rhus coriaria extract on MDA-MB-231, MCF-7 and
T47D breast cancer cell lines
We wanted first to test the anti-cancer activity of Rhus coriaria extract
(RCE) on breast cancer cells. Toward this, we measured the effect of different
concentrations of the RCE (0, 50, 100, 200, 400 and 600 μg/mL) on the proliferation
of three different breast cancer cell lines (MDA-MB-231, MCF-7 and T47D). Our
results indicate that RCE decreased cellular viability in concentration and timedependent manners (Fig. 3A–C).
By determining the IC50 –which is the concentration at which the drug cause
50% inhibition - for each cell line, it appears that T47D and MDA-MB-231 exhibit
a greater sensitivity to RCE compared to the MCF-7 cells (Table 1). Then we
focused on MDA-MB-231 cells since it belongs to the highly aggressive triple
negative breast cancer for further investigation.

IC50 (µg/mL)
24 h

48 h

72h

MDA-MB-231

437

305

283

T47D

374

261

229

MCF-7

ND

510

433

Table 1: IC50 values for each cell line at the indicated time of treatment
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Figure 3: Rhus coriaria extract (RCE) inhibited cellular viability of (A)MDA-MB231, (B) T47-D and (C) MCF-7 breast cancer cell lines treated with or without the
indicated concentrations of RCE for 24h, 48h and 72h. Data represent the mean of
five independent experiments carried out in triplicate. Statistical analysis for cell
viability data was performed using one-way ANOVA followed by LSD Post-Hoc test
(*p < 0.05, **p < 0.005, ***p < 0.001).
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3.2 Inhibition of proliferation recovery after removal of Rhus coriaria extract
Next, we examined whether or not, RCE can suppress the potential of breast
cancer cells to recover proliferative capability. Cells were first treated with the
indicated concentration of RCE for 24 h, and then washed with PBS and placed in
fresh complete media in the absence of RCE, and allowed to grow for another 48 h
before assessing cell viability by cell counting. Figure 4, indicates that MDA-MB231 cells failed to recover proliferative capability as the number of viable cells kept
reducing even after RCE removal. Thus, our result indicates that RCE exerts an
irreversible anti-proliferative effect on breast cancer cells.

Figure 4: Inhibition of cellular viability recovery after RCE removal. MDA-MB-231
cells were exposed to RCE for 24 h, then, cells were washed and allowed to grow for
another 48 h in fresh complete media. Cell viability was monitored using the Muse
Cell Analyzer. Data represent the mean ± SEM of three independent experiments.
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3.3 Induction of G1 arrest in Rhus coriaria treated cells
To investigate the mechanism(s) underlying the inhibitory activity of RCE
on breast cancer cells, we examined its effect on cell cycle progression. MDA-MB231 cells were treated with indicated concentrations of RCE for 24 h and 48 h and
were subjected to cell cycle analysis. Treating cells with RCE caused a significant
inhibition of cell cycle progression in MDA-MB-231 cells at 24 and 48 h leading to
an increase in the G1 population.

Figure 5: Induction of cell cycle arrest at G1 in MDA-MB-231 cells. Cell cycle
distribution analysis of RCE-induced G1 cell-cycle block. MDA-MB 231 cells were
first treated with RCE at the indicated concentrations for 24 h and 48 h, and then
analyzed with Muse Cell Analyzer.
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3.4 Induction of senescence in Rhus coriaria treated cells
The induction of cell cycle arrest at G1 phase prompted us to examine if the
arrested cells did indeed undergo senescence. Our results show that senescence was
detected after treating the cells for 48 h. Almost 21% of the cells that expressed
SA-β-galctosidase were detected at 200 μg/mL of RCE. After 96 h of treatment
senescent cells nearly doubled at the same concentration. Taken together, these data
suggest that induction of senescence might contribute to the inhibitory effect of RCE
on the proliferation of MDA-MB-231 cells (fig. 6).

Figure 6: Induction of senescence in MDA-MB-231 cells. MDA-MB 231 cells were
incubated with RCE (200 μg/mL) for 48 and 96 hours and stained for SA-βGalactosidase activity to detect senescence. Data are representative of three
independent experiments. Statistical analysis was performed using one-way ANOVA
(*p < 0.05, **p < 0.005, ***p < 0.001).
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3.5 Minimal induction of apoptosis in MDA-MB-231 treated with Rhus coriaria
extract
Since RCE decreased cellular viability in MDA-MB-231 cell, we decided to
investigate the mechanism by which RCE decreased cellular viability. First we
checked whether or not the decreased viability is associated with apoptosis.
Therefore, we stained for Annexin V to determine the percentage of apoptotic cells
induced by RCE after 48 h treatment. Exposure to RCE did not lead to a significant
change in the early stage apoptotic population (Annexin V+/7-AAD−). An increase
but still minimal in the late stage apoptotic/necrotic cells (Annexin V+/PI+) (fig.7
AB) was observed at highest RCE concentration, suggesting minimal apoptotic cell
death induced by RCE in MDA-MB-231 cells. Apoptosis was further assessed by
Poly (ADP-ribose) polymerase (PARP) cleavage.

PARP is a nuclear enzyme

involved in DNA repair, and it is a well-known substrate for caspase-3 cleavage
during apoptosis[91]. Cells treated with etoposide (50 μM) for 24 h, a condition that
was reported to induce apoptosis, was used as positive control. Despite the high
level of concentration- and time-dependent cell death observed by cell toxicity and
cell counting assay during the first 72 h of RCE treatment, very little PARP
cleavage, was observed in RCE-treated MDA-MB-231 cells (fig. 7C). Altogether,
Annexin V staining and PARP cleavage data support the conclusion of minimal
induction of apoptosis by RCE in MDA-MB-231 cells.
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Figure 7: Minimal induction of apoptosis in the MDA-MB-231 cells. (A-B) Annexin
V binding was carried out using Annexin V & Dead Cell kit (Millipore). Cells were
treated with or without increasing concentrations of RCE for 48 h. Detached and
adherent cells were collected and stained with Annexin V and 7-AAD and then the
events for early and late apoptotic cells were counted by Muse Cell Analyzer. Data
represent the mean ± SEM of at least 3 independent experiments. Statistical analysis
was performed using ANOVA followed by LSD Post-Hoc test to determine the
significance (*p < 0.05, **p < 0.005, ***p < 0.001). (C) Western blot analysis of
PARP cleavage in MDA-MB-231. Cells were treated with increasing concentrations
of RCE (200, 400 and 600 μg/mL) for 48 h and 72 h. Exposure of cell to etoposide
(50 μM) for 24 h was used as a positive control for apoptosis.

3.6 Induction of autophagy in MDA-MB-231 treated with Rhus coriaria extract
Eosin/hematoxylin staining of MDA-MB-231 cells treated with RCE
revealed massive cytoplasmic vacuolation that might indicate induction of
autophagy (Fig. 8A). In order to determine whether indeed this vacuolation resulted
from activation of autophagy. And to further confirm autophagy induction in RCEtreated MDA-MB-231 cells, LC3II accumulation was analyzed by Western blotting
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in MDA-MB-231 treated with various concentrations of RCE. RCE induced a
concentration-dependent accumulation of the LC3-II (fig. 8B). The expression of
p62 (SQSTM1) was also evaluated. There was a concentration-dependent decrease
in p62 (SQSTM1) (fig. 8B). Hence, the conversion of LC3I/II along with the
downregulation of p62 (SQSTM1) confirm the formation of autophagosome in
RCE-treated MDA-MB-231 cells. Next we assessed the expression of beclin-1.
Western blotting data showed that the level of Beclin-1 also increased in
concentration-dependent manner. Taken together, Western blotting results along
with eosin/hematoxylin staining, confirms the activation of autophagy in breast
cancer cells in response to RCE treatment.

Figure 8: Induction of autophagy in RCE treated MDA-MB-231 cells. (A) MDA-MB231 cells were treated for 48 h with RCE (400 µg/mL) and then stained with eosinhematoxylin. (B) Cells were treated with or without increasing concentration of RCE for 48 h,
then whole cell proteins were extracted and subjected to Western blot analysis for LC3II,
62(SQSTM1), beclin1 and β-actin (loading control) proteins.
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3.7 Autophagy blockage reduces cell death and senescence in Rhus coriariatreated cells
The observation that RCE induces robust cell death in MDA-MB-231 cells and, that
induction of apoptosis is minimal raised the question of whether autophagy is
responsible for the cytotoxicity activity of RCE through activation of type II
programmed cell death and therefore its blockade by autophagy inhibitors might
render cells less susceptible to RCE treatment. We used two widely used autophagy
inhibitors, 3-methyladenine (3-MA), phosphatidylinositol 3-phosphate kinase
(PI3K) inhibitor, which blocks autophagosome formation[69] and chloroquine
(CQ), inhibitor of lysosomal acidification, which blocks the fusion between
autophagosomes and lysosomes[53]. Results showed that autophagy was markedly
inhibited by 3-MA, evident by decreased conversion of LC3-I to LC3-II (fig.9A).
However, when cells were pre-treated with CQ, LC3-II protein accumulated to some
extent (fig.9A). Next we tested the effect of these inhibitors on the cellular viability
of MDA-MB-231 cells treated with RCE. We found that cell viability was markedly
improved in the presence of 3-MA or CQ when compared with RCE alone,
suggesting that RCE-induced cell death is significantly dependent on autophagy
induction (fig. 9B). Furthermore, inhibition of autophagy neither increased nor
reduced the level of cleaved PARP, suggesting that RCE-mediated apoptosis and
autophagy in MDA-MB-231 might occur independently from each other (fig. 9B).
Because blockade of autophagy improved cell viability, and because SA-βgalactosidase was also detected in autophagic cells, we asked the question whether
blocking autophagy can also affect senescence in RCE-treated cells. Figure
9D shows that the number of senescent cells in wells containing both CQ and RCE
is significantly lower than that in well treated with RCE alone. These results suggest
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that autophagy and senescence are linked events and that induction of senescence is
at least partly dependent upon the activation of autophagy.

Figure 9: Effects of autophagy inhibitors on cell death, apoptosis and senescence. (A)
Analysis of LC3-II accumulation in MDA-MB-231 cells. Cells were pre-treated with
or without 3-MA (5 mM) or CQ (50 μM) for 1 h and then RCE was added at the
indicated concentrations for 48 h. Proteins were extracted and LC3-II accumulation
was determined by western blot. (B) Inhibition of autophagy reduces cell death
induced by RCE. MDA-MB-231 cells were pre-treated as described above and treated
for 48 h with 400 or 600 μg/mL RCE. Data are representative of three independent
experiments. Statistical analysis of cell viability on control or treated cells was
performed using one-way ANOVA followed by LSD Post-Hoc test to determine
significance (*p < 0.05, **p < 0.005, ***p < 0.001). (C) Western blot of cleaved
PARP in cells pre-treated with and without autophagy inhibitors. (D) Effect of
autophagy blockade on RCE-induced senescence. Cells were treated as described in A
and stained for SA-β-Gal activity to detect senescence. Data are representative of three
independent experiments. Statistical analysis of senescent cells count on control or
treated cells was performed using one-way ANOVA and univariate test to determine
significance (**p < 0.01).
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3.8 Rhus coriaria induces DNA damage as an early event that precedes autophagy
Next, we sought to investigate whether RCE induces DNA damage in MDAMB-231 cells. Western blotting analysis revealed a concentration-dependent
increase in the levels of phosphorylated H2AX (γH2AX) (fig. 10A), indicating an
accumulation of double strand breaks in treated cells. In order to assess whether
DNA damage is an early event, a time-course measurement of γH2AX in cells
treated with 400 μg/mL RCE was carried out. We found that activation of γH2AX
occurred as early as 6 h post-treatment (fig. 10B). To further test whether DNA
damage precedes autophagy, MDA-MB-231 cells were first incubated for 1 h with
the autophagy inhibitor CQ and then treated with the indicated concentration of
RCE. Figure 10C, shows that inhibition of autophagy did not prevent DNA damage
in treated cells. Taken together, these results indicate that DNA damage is an earlier
event in RCE-treated cells. This damage might then serve as a trigger for
downstream responses. Based on these findings, we hypothesize that DNA damage
is an early response to RCE that might contribute to the induction of autophagy in
MDA-MB-231 cells.
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Figure 10: Accumulation of DNA damage in RCE treated MDA-MB-231. (A)
Concentration-dependent accumulation of γH2AX, in RCE-treated cells. MDA-MB231 cells were treated with and without increasing concentrations of RCE for 48 h and
DNA damage was analyzed, by determining the level of γH2AX accumulation using
anti- phospho-H2AX (ser 139) antibody. (B) Time-course measurement of DNA
damage in treated MDA-MB-231 cells. Cells were treated with 400 μg/mL RCE and
DNA damage was examined, at different time-point (6, 12, 24 and 48 h). (C) Effect of
autophagy inhibitor on the accumulation of DNA damage. Cells were pre-treated with
CQ (50 μM) for 1 h before adding RCE (400 and 600 μg/mL) for 48 h. Cells were then
harvested and γH2AX level was determined by western blot.
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Chapter 4: Discussion
Accumulating evidences demonstrated that several natural compounds derived
from plants were found to play a positive role in cancer prevention and treatment
through modulating autophagy, which became a promising target for developing
potential therapeutic drugs[92]. In our study we investigated the anticancer activity of
Rhus coriaria on human breast cancer cells. Our work demonstrated that Rhus coriaria
ethanolic extract (RCE) decreased the cellular viability of three breast cancer cell lines
(MDA-MB-231, T47D and MCF-7) in a time- and a concentration-dependent manner.
Moreover, it induced an irreversible effect on the survival of the MDA-MB-231 cell
line after the removal of RCE since cells were unable to recover their proliferation.
RCE induced irreversible cell cycle arrest at G1 phase and senescence detected by the
elevated expression of SA-β-Gal. Furthermore, we found that RCE induced autophagy
which was the main mechanism of cell death. Induction of DNA damage was also
detected by increased expression of γH2AX.
Inhibition of cellular viability by RCE was observed on three breast cancer cell
lines although they obtain different characteristics. MDA-MB-231 cell line is
originated from adenocarcinoma and the state of its estrogen and progesterone
receptors are negative and its p53 gene is mutated. T47D is derived from ductal
carcinoma and the state of its estrogen and progesterone receptors are positive and its
p53 gene is mutated as well. MCF-7 is originated from adenocarcinoma and the state
of its estrogen receptor is positive while the progesterone receptor is negative and its
p53 gene is wild type[93]. However we focused on MDA-MB-231 cell line since it
belongs to the TNBCs which are characterized by being a highly aggressive form of
breast cancer with poor survival rate[94].
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Treatment with chemotherapy is not always toxic to all cancer cells; some of
the cells survive the treatment, recover and resume their proliferation[95]. Therefore,
it is challenging to find drugs that induce irreversible inhibition to uncontrolled cellular
growth. Interestingly, our work demonstrated that RCE was able to suppress the
capability of MDA-MB-231 cells to recover its proliferative potential at concentrations
of 400 and 600 µg/mL, which were the concentrations at which cell death was detected.
It has been proposed that cellular senescence refers to permanent cell cycle
arrest in G1 phase in response to different stressors[43] as cells lose the ability to
proliferate[44]. In line with the previously published results, our results showed that
RCE induced cell cycle arrest at G1 phase and cellular senescence marked by increased
expression of SA-β-Gal activity after 48 h of treatment.
Some tumors were found to undergo both autophagic cell death and apoptosis
in response to cancer therapy[69]. Apoptosis and autophagy are not always separate
events, there might be a crosstalk between them[53]. Here, we showed that RCE
prompted minimal apoptosis while the main cellular death mechanism was autophagy.
However, the conditions under which autophagy can function as a primary cell death
mechanism remain to be defined. As discussed earlier, p62/SQSTM 1 is normally
degraded during autophagy and accumulates when autophagy is impaired, as has been
shown in autophagy-deficient mice[66]. This, in agreement with our results, which
illustrated that P62/SQSTM1 was decreased with increasing concentrations of RCE.
Several studies revealed that when autophagy is inhibited, apoptosis is promoted in
cancer cells[53]. Unlike these studies, our data showed that when autophagy was
inhibited by CQ, there was no induction of apoptosis, suggesting that these two
pathways occurred independently.
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In cellular context, autophagy has dual function in cellular survival and death.
Autophagy promote cellular survival as a protective mechanism due to cellular
stressors, however extensive autophagy can lead to cell death[96]. Recently, DNA
damage has been shown to induce autophagy, but the exact mechanisms by which
DNA damage triggers autophagy are still unclear[97]. As we observed in our results,
γH2AX was induced in a dose-dependent manner upon treating the cells with RCE and
the inhibition of autophagy did not cause any change in γH2AX expression suggesting
that DNA damage is a prerequisite for autophagy. In addition to that DNA damage
was also shown to cause cells to undergo senescence[98]. Moreover, it was shown that
stress-induced senescence occur in tumor cells in vitro and in vivo through the
exposure of cells to cytotoxic agents that are found to cause DNA damage[44]. Here
we demonstrated that cellular senescence was detected after 48 h while DNA damage
was detected as early as 6 h suggesting that DNA damage is an early step that precedes
cellular senescence. We propose that this damage might serve as a trigger for
downstream responses leading to autophagy, senescence and cell death.
It has been shown that increased autophagic activity was associated with
senescence in different models, suggesting that autophagy might be an integrated part
of senescence program[99]. A positive correlation between autophagy and senescence
was also observed where the inhibition of autophagy decreased the number of
senescent cells[100]. Moreover, it was shown that inhibition of autophagy by 3-MA
decreased the number of SA-β-Gal- positive cells[101]. Here, we showed that low
concentration of RCE (200 µg/mL) caused autophagy in association with cellular
senescence and when autophagy was inhibited by CQ there was a decrease in senescent
cells.
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Figure 11: Hypothetical model demonstrating the differential effect of Rhus coriaria
Extract.

In summary, our data are consistent with a model shown in Figure 11, in which
treatment with RCE induce autophagy in MDA-MB-231 TNBC cell line.

The

magnitude of damage, which depends upon the concentration of RCE, determines the
response of the cells. We propose that at lower concentration of RCE (100 and 200
µg/mL) there was a limited induction of γH2AX, where cells respond by triggering
autophagy as a survival mechanism followed by cellular senescence. On the other
hand, higher concentrations of RCE (400 and 600 µg/mL) caused excessive amounts
of DNA damage that was beyond the capacity of the cell to repair, thus results in
increased autophagy which ultimately leads to cell death.
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Chapter 5: Conclusion
In conclusion, our study demonstrated, for the first time, the potential role of
Rhus coriaria, as an anti-breast cancer agent in vitro. This study provides preliminary
data that proposes Rhus coriaria as a valuable source of potentially new natural antibreast cancer compound(s) that act by triggering senescence and autophagic cell death.
Further exploration of this plant is urged in order to identify the bioactive
phytochemical(s) conferring its anti-breast cancer activity.
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